Results 21 to 30 of about 91,544 (273)

Anti CD38 monoclonal antibodies for multiple myeloma treatment

open access: yesHuman Vaccines & Immunotherapeutics, 2022
CD38 is a transmembrane glycoprotein with ectoenzymatic activity and is highly and uniformly expressed on multiple myeloma (MM) cells. CD38 is expressed also at relatively low levels on normal lymphoid and myeloid cells, and in some tissues of non ...
Alessandro Gozzetti   +6 more
doaj   +1 more source

Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?

open access: yesCells, 2020
During a time span of just a few years, the CD38 antibody, daratumumab, has been established as one of the most important new drugs for the treatment of multiple myeloma, both in the relapsed/refractory setting and, more recently, as a first-line ...
Torben Plesner   +2 more
doaj   +1 more source

Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia [PDF]

open access: yes, 2014
Chronic myeloid leukemia (CML) is a stem cell (SC) neoplasm characterized by the BCR/ABL1 oncogene. Although mechanisms of BCR/ABL1-induced transformation are well-defined, little is known about effector-molecules contributing to malignant expansion and ...
Bilban, Martin   +15 more
core   +1 more source

Rising of intracellular NAD+ level and oppositely directed changes in CD38 expression in hippocampal cells in experimental Alzheimer’s disease

open access: yesСибирский научный медицинский журнал, 2021
The aim of the study was to assess the level of NAD+ in the brain of mice treated with beta-amyloid (Aβ), as well as to determine the activity of ADP-ribosyl cyclase/CD38 and the number of CD38-immunopositive neurons, astrocytes and endothelial cells ...
A. A. Semenova   +4 more
doaj   +1 more source

Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease [PDF]

open access: yes, 2014
© 2014 John Wiley & Sons Ltd. Defining the prognosis of individual cancer sufferers remains a significant clinical challenge. Here we assessed the ability of high-resolution single telomere length analysis (STELA), combined with an experimentally ...
Allan, James M.   +14 more
core   +1 more source

Plasmablastic Lymphoma with Primary Impairment of Bone Marrow in a HIV-Negative Patient: A Literature Review and a Case Report

open access: yesКлиническая онкогематология, 2022
Background. Plasmablastic lymphoma (PBL) is a rare variant of large B-cell lymphoma. This disease is usually associated with HIV infection and is predominantly identified in male patients. Tumor lesion is typically localized in oral cavity.
Maiya Valerevna Firsova   +3 more
doaj   +1 more source

Lymphoid priming in human bone marrow begins before expression of CD10 with upregulation of L-selectin. [PDF]

open access: yes, 2012
Expression of the cell-surface antigen CD10 has long been used to define the lymphoid commitment of human cells. Here we report a unique lymphoid-primed population in human bone marrow that was generated from hematopoietic stem cells (HSCs) before onset ...
Crooks, Gay M   +7 more
core   +1 more source

Daratumumab

open access: yesIndian Journal of Medical and Paediatric Oncology, 2020
Multiple myeloma is a proliferative disorder of plasma cells in the bone marrow with excessive monoclonal protein production. Despite the evolution of multiple drugs and management strategies including maintenance and autologous stem cell transplantation,
Vishnu Gopal, Biswajit Dubashi
doaj   +1 more source

Clinical findings and immunophenotypic profile of plasma cell leukemia: a retrospective study in a comprehensive cancer center in Turkey

open access: yesMedicine Science, 2021
Plasma cell leukemia (PCL) is a rare (1-2 %) aggressive plasma cell dyscrasia (PCD) with a poor prognosis and characterized by the presence of more than 20% circulating plasma cells (PCs).
Nurgul Ozcan   +7 more
doaj   +1 more source

CD38: A NAADP degrading enzyme [PDF]

open access: yesFEBS Letters, 2011
The role of the multifunctional enzyme CD38 in formation of the Ca(2+)-mobilizing second messenger nicotinic acid adenine dinucleotide phosphate (NAADP) was investigated. Gene silencing of CD38 did neither inhibit NAADP synthesis in intact Jurkat T cells nor in thymus or spleen obtained from CD38 knock out mice.
Schmid, Frederike   +4 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy